Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Raúl Márquez Vázquez"'
Autor:
Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based ch
Externí odkaz:
https://doaj.org/article/6a0a2a80b0c94cb1a14431371e664115
Autor:
Raúl Márquez Vázquez, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Jesus Soberino, Susana de la Cruz Sánchez, Peter Schmid, Aleix Prat, Miguel Angel Seguí-Palmer, María Gión Cortés, Andrea Malfettone, Vicente Carañana, Javier Cortes, Lourdes Calvo, Begoña Bermejo, Manuel Ruiz Borrego, Giuseppe Curigliano, Jose Luis Alonso, Jose Perez-Garcia, Elena López-Miranda
Publikováno v:
European Journal of Cancer. 148:382-394
Background Pembrolizumab has modest activity if used in patients with hormone-receptor–positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77826c81ce42c3ca11452e8188ac513
https://doi.org/10.1016/j.ejca.2021.02.028
https://doi.org/10.1016/j.ejca.2021.02.028
Autor:
José Manuel Pérez-García, Antonio Llombart-Cussac, Esther Holgado, Giuseppe Curigliano, Elena López Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruiz Borrego, Miguel Sampayo, Miguel Àngel Seguí, Jesus Soberino, Andrea Malfettone, Peter Schmid, Javier Cortés
Publikováno v:
Cancer Research. 80:P3-09
BACKGROUND: Studies of checkpoint inhibitor monotherapy have shown only modest activity in hormone receptor (HR)-positive (+)/human epidermal growth factor receptor 2 (HER2)-negative (-) metastatic breast cancer (MBC). However, pembrolizumab (P) adde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e349ff29c5e24cae828097f91532800
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
Publikováno v:
Cancer Breaking News. 5:36-40
Approximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2), which represents an adverse prognostic factor. The therapeutic landscape for this type of breast cancer has been transformed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7256226a4cf216abc44df97e3e147f96
https://doi.org/10.19156/cbn.2017.0058
https://doi.org/10.19156/cbn.2017.0058
Publikováno v:
Future oncology (London, England). 14(7s)
Triple-negative breast cancers are defined as tumors negative for estrogen receptors, progesterone receptors and human EGFR2. These tumors exhibit diverse biological behavior and have a poor prognosis; chemotherapy is the mainstay of treatment. The f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c953d188869730ccce84d5132dba723
https://pubmed.ncbi.nlm.nih.gov/29611754
https://pubmed.ncbi.nlm.nih.gov/29611754
Autor:
Miguel Sampayo, Jose Manuel Perez Garcia, Manuel Ruiz Borrego, Antonio Llombart, Begoña Bermejo, Vicente Carañana, María Gión Cortés, Jose Luis Alonso, Javier Cortes, Raúl Márquez Vázquez, Giuseppe Curigliano, Susana de la Cruz Sánchez, Miguel Ángel Seguí, Esther Holgado, Aleix Prat, Lourdes Calvo, Peter Schmid
Publikováno v:
Cancer Research. 78:CT152-CT152
BACKGROUND: Preliminary results with MK3475 (pembrolizumab) in heavily pretreated Estrogen Receptor (ER)-positive/ Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic breast cancer (MBC) patients have shown promising antitumor activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::389277d38cc6114a02c62dba00d502b3
https://doi.org/10.1158/1538-7445.am2018-ct152
https://doi.org/10.1158/1538-7445.am2018-ct152
Autor:
David Álvarez Martínez, Ana Pastor Rodríguez-Moñino, Sara Artola Menéndez, Ramon Pujol Farriols, Raúl Márquez Vázquez, Cristóbal León Gil, Paloma Casado Pérez, Raquel Barba Martín, Fernando de Álvaro Moreno, Pedro Conthe Gutiérrez, Inmaculada Alfageme Michavilla, Javier García Alegría, Albert Jovell Fernández, Pedro Javier Cañones Garzón, Arturo Lisbona Gil, Luis Escosa Royo
Publikováno v:
Medicina Clínica. 134:505-510
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08a5db2b9b3f11b6e11a48c4ab80fba4
https://doi.org/10.1016/j.medcli.2009.12.002
https://doi.org/10.1016/j.medcli.2009.12.002